Cue Biopharma (NASDAQ:CUE) — Market Cap & Net Worth
Market Cap & Net Worth: Cue Biopharma (CUE)
Cue Biopharma (NASDAQ:CUE) has a market capitalization of $26.56 Million ($26.56 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #24119 globally and #4972 in its home market, demonstrating a 5388.99% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cue Biopharma's stock price $30.42 by its total outstanding shares 91237736 (91.24 Million). Analyse CUE cash flow conversion to see how efficiently the company converts income to cash.
Cue Biopharma Market Cap History: 2018 to 2026
Cue Biopharma's market capitalization history from 2018 to 2026. Data shows growth from $428.82 Million to $2.78 Billion (12.23% CAGR).
Index Memberships
Cue Biopharma is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #693 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2307 of 3165 |
Weight: Cue Biopharma's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cue Biopharma Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cue Biopharma's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
10.71x
Cue Biopharma's market cap is 10.71 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $428.82 Million | $1.14 Million | -$38.98 Million | 375.30x | N/A |
| 2019 | $1.45 Billion | $3.46 Million | -$36.70 Million | 418.85x | N/A |
| 2020 | $1.14 Billion | $3.15 Million | -$44.78 Million | 361.85x | N/A |
| 2021 | $1.03 Billion | $14.94 Million | -$44.16 Million | 69.06x | N/A |
| 2022 | $260.03 Million | $1.25 Million | -$53.01 Million | 208.86x | N/A |
| 2023 | $240.87 Million | $5.49 Million | -$50.73 Million | 43.87x | N/A |
| 2024 | $99.45 Million | $9.29 Million | -$40.67 Million | 10.71x | N/A |
Competitor Companies of CUE by Market Capitalization
Companies near Cue Biopharma in the global market cap rankings as of May 4, 2026.
Key companies related to Cue Biopharma by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Cue Biopharma Historical Marketcap From 2018 to 2026
Between 2018 and today, Cue Biopharma's market cap moved from $428.82 Million to $ 2.78 Billion, with a yearly change of 12.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.78 Billion | +9860.71% |
| 2025 | $27.86 Million | -71.98% |
| 2024 | $99.45 Million | -58.71% |
| 2023 | $240.87 Million | -7.37% |
| 2022 | $260.03 Million | -74.80% |
| 2021 | $1.03 Billion | -9.59% |
| 2020 | $1.14 Billion | -21.20% |
| 2019 | $1.45 Billion | +237.77% |
| 2018 | $428.82 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Cue Biopharma was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $26.56 Million USD |
| MoneyControl | $26.56 Million USD |
| MarketWatch | $26.56 Million USD |
| marketcap.company | $26.56 Million USD |
| Reuters | $26.56 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cue Biopharma
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical tria… Read more